The discovery of a series of HCC-specific TAAs provides the rationale for applying ADCs in HCC treatment: glypican-3 (GPC3) [134], AFP, epithelial cell adhesion molecule (EpCAM) [135], tumor endothelial marker 1 (TEM1, or endosialin) [136], MAGE-A, NY-ESO-1 [137], and claudin-6 (CLDN6) [138]. This evidence concerns the gene CD248 and hepatocellular carcinoma.